Other

The Brigham and Women's Hospital, Inc.

Tucker Collins

Michael A Gimbrone, Jr

David J Pinsky

Myron I Cybulsky

This invention provides methods for determining whether an agent increases PPAR-&#x3b3;-mediated inhibition of Egr-1 expression. This invention also provides methods for inhibiting the onset of atherosclerosis in a transplanted organ. This invention further provides numerous methods for treating disorders, and/or inhibiting the onset of disorders or disorder-related complications by using PPAR-&#x3b3; agonists. This invention still further provides related methods for inhibiting cancer metastasis, treating and inhibiting the onset of a heart attack, and treating burn and crush injuries. Finally, this invention provides related articles of manufacture.

Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods

The invention relates to novel endothelial cell-leukocyte adhesion molecules designated ATHERO-ELAM. ATHERO-ELAM molecules are expressed on cultured endothelial cells stimulated with bacterial LPS and selectively mediate the binding of monocytes to the endothelial cells. Monoclonal antibodies specific for ATHERO-ELAM bind to vascular endothelial cells involved in early atherosclerotic lesions, but not to vascular endothelial cells from uninvolved arterial tissue. ATHERO-ELAM and antibodies directed to ATHERO-ELAM may be used in identifying early atherosclerotic lesions and in treating and preventing atherosclerosis.

Growing community of inventors

Cohasset, MA, United States of America

Tucker Collins